Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or ...

Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season.

Despite being back in the season of sniffles and sick days, Washington state will be extra equipped to battle the spread of respiratory viruses this year.

Dr Xand van Tulleken has addressed public confusion surrounding different types of vaccination, amid fears of a "tripledemic" ...

Expanded access to addiction treatment and the overdose-reversal med naloxone likely prompted a 37% reduction in OD deaths ...

NanoViricides, Inc. (NYSE Amer.: NNVC ) (the “Company”), a clinical stage global leader in broad-spectrum antiviral ...

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

Dr Xand's thoughts comes amidst rising concern over a 'tripledemic' this winter, as cases of people catching Covid, flu and ...